Pharmaceuticals

Alcon Inc. (ACL) recently announced that its board of directors has given the nod for its merger with Novartis AG (NVS). Novartis plans to pay $168 per share to acquire the remaining 23% share of Alcon it does not already own. Per the terms of the agreement, the merger consideration will consist...

Akron (NASDAQ: AKRX) making fresh session and 52-week highs today. Shares of Akron were trading at $6.20, up 2.6% from yesterday's close.

A late-day sell-off, for the third consecutive day, witnessed the markets go slightly lower on Wednesday. On a lackluster day of major events that could negatively impact the indices, markets were partially affected by a rise in Treasury yields. Euro-zone debt crisis re-surfaced concerns among...

Novartis (NYSE: NVS) is trading lower today. At last check, NVS was trading at $58.55 in pre-market trading, down 0.75% from yesterday.

A late-day sell-off, for the third consecutive day, witnessed the markets go slightly lower on Wednesday. On a lackluster day of major events that could negatively impact the indices, markets were partially affected by a rise in Treasury yields. Euro-zone debt crisis re-surfaced concerns among...

Cypress Bioscience, Inc. (NASDAQ: CYPB) is indicated to open higher in Thursday trading after the company entered into an agreement and merger agreement with Ramius Value for $6.50 per share in cash. Accuray Incorporated (NASDAQ: ARAY) is up 1.4% in pre-market trading. Copart, Inc. (NASDAQ: CPRT...

Analysts at Macquarie Capital Markets downgrade Dr. Reddy's Laboratories Limited (NYSE: RDY) from "outperform" to "neutral." RDY's shares lost 1.78% to close at $39.82 yesterday. More Analyst Ratings here

GlaxoSmithKline (NYSE: GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced an agreement for the development and commercialization of IPX066 outside the United States and Taiwan. IPX066, an investigational product under development for the...

Cusick's Corner All eyes are going to be on the EU for the next couple of days as foreign ministers meet to discuss debt issues, specifically how they are going to continue to support it. The Euro, FXE, pulled back in front of this meeting, which has given way to support in the Dollar, UUP....

We are maintaining our Neutral recommendation on Optimer Pharmaceuticals Inc. (OPTR) with a target price of $12.00. Headquartered in San Diego, California and founded in 1998, Optimer Pharmaceuticals Inc. focuses on discovering, developing and commercializing anti-infective products. The...

ProShares UltraShort Silver (ETF) (NYSE: ZSL) gained 4.78% today, and closed at $11.41 as silver dropped more than 3%. ZSL had a volume of 2.64M traded shares. ProShares UltraShort FTSE/Xinhua China 25 (NYSE: FXP) jumped 4.73% as China Mobile Ltd. (ADR) (NYSE: CHL) fell 1.12%. CNOOC Limited (ADR...

C.R. Bard (BCR), which makes medical, surgical, diagnostic and patient care devices, has issued an upbeat outlook for fiscal 2011. At its annual analyst meeting, the New Jersey-based medical devices maker stated that it envisions adjusted (excluding special items) earnings per share for 2011 to...

We are maintaining our Neutral recommendation on Optimer Pharmaceuticals Inc. (OPTR) with a target price of $12.00. Headquartered in San Diego, California and founded in 1998, Optimer Pharmaceuticals Inc. focuses on discovering, developing and commercializing anti-infective products. The...

C.R. Bard (BCR), which makes medical, surgical, diagnostic and patient care devices, has issued an upbeat outlook for fiscal 2011. At its annual analyst meeting, the New Jersey-based medical devices maker stated that it envisions adjusted (excluding special items) earnings per share for 2011 to...

Teva Pharmaceutical Industries Ltd. (TEVA) recently announced encouraging results on its multiple sclerosis candidate, laquinimod. Initial data on laquinimod, which is being developed with Active Biotech, indicated that patients treated with laquinimod experienced a statistically significant...